Impact of extracardiac pathology on head growth in fetuses with congenital heart defect

A. E. L. VAN NISSELROOIJ[1], F. A. R. JANSEN[1], N. VAN GELOVEN[2], I. H. LINSKENS[3], E. PAJKRT[3], S.-A. CLUR[4], L. A. RAMMELOO[4], L. ROZENDAAL[5], J. M. M. VAN LITH[1], N. A. BLOM[5] and M. C. HAAK[1]

[1]*Department of Obstetrics and Fetal Medicine, Leiden University Medical Center, Leiden, The Netherlands;* [2]*Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands;* [3]*Amsterdam UMC, University of Amsterdam, Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands;* [4]*Department of Paediatric Cardiology, Emma Children's Hospital, University Medical Center Amsterdam, Amsterdam, The Netherlands;* [5]*Department of Paediatric Cardiology, Leiden University Medical Center, Leiden, The Netherlands*

CONTRIBUTION

What are the novel findings of this work?
The impaired (head) growth that is encountered in fetuses with a congenital heart defect (CHD) is more likely explained by the presence of placenta-related pathology and genetic anomaly than as an effect of alteration in fetal hemodynamics caused by the CHD itself.

What are the clinical implications of this work?
Future research on brain development in CHD fetuses, in relation to overall growth and additional pathology, is required to gather knowledge on prognostic factors for neonatal outcome, which is essential for prenatal counseling.

ABSTRACT

Objective *Neurodevelopmental delay is frequently encountered in children with a congenital heart defect (CHD). Fetuses with major CHD have a smaller head circumference (HC), irrespective of altered cerebral flow or brain oxygenation. This cohort study compared head growth in cases with isolated vs those with non-isolated CHD to evaluate the effect of additional pathology on head size in these fetuses.*

Method *All CHD cases diagnosed prenatally in the period January 2002–July 2014 were selected from our regional registry, PRECOR. Cases of multiple pregnancy, and those affected by maternal diabetes, severe fetal structural brain anomalies or functional CHD were excluded. Subjects were divided into groups according to whether the CHD was isolated, and the non-isolated group was subdivided into three groups: cases with genetic anomaly, extracardiac malformation or placental pathology. In both isolated and non-isolated CHD groups, CHDs were also grouped according to their potential effect on aortic flow and oxygen saturation. Mean HC Z-scores at 20 weeks and increase or decrease (Δ) of HC Z-scores over the course of pregnancy were compared between isolated and non-isolated groups, using mixed linear regression models.*

Results *Included were 916 cases of CHD diagnosed prenatally, of which 378 (41.3%) were non-isolated (37 with placental pathology, 217 with genetic anomaly and 124 with extracardiac malformation). At 20 weeks, non-isolated cases had significantly lower HC Z-scores than did isolated cases (Z-score = −0.70 vs −0.03; P < 0.001) and head growth over the course of pregnancy showed a larger decrease in this group (Δ HC Z-score = −0.03 vs −0.01 per week; P = 0.01). Cases with placental pathology had the lowest HC Z-score at 20 weeks (Z-score = −1.29) and the largest decrease in head growth (Δ HC Z-score = −0.06 per week). In CHD subjects with a genetic diagnosis (Z-score = −0.73; Δ HC Z-score = −0.04 per week) and in those with an extracardiac malformation (Z-score = −0.49; Δ HC Z-score = −0.02 per week), HC Z-scores were also lower compared with those in subjects with isolated CHD. CHDs that result in low oxygenation or flow to the brain were present more frequently in isolated than in non-isolated cases.*

Conclusions *Smaller HC in fetuses with CHD appears to be associated strongly with additional pathology.*

Correspondence to: Dr A. E. L. van Nisselrooij, Department of Obstetrics and Fetal Medicine, Leiden University Medical Center, K6-35, Albinusdreef 2, 2333 ZA Leiden, The Netherlands (e-mail: a.e.l.nisselrooij@lumc.nl)

ORIGINAL PAPER

Placental pathology and genetic anomaly in particular seem to be important contributors to restricted head growth. This effect appears to be irrespective of altered hemodynamics caused by the CHD. Previously reported smaller HC in CHD should, in our opinion, be attributed to additional pathology. Neurodevelopment studies in infants with CHD should, therefore, always differentiate between isolated and non-isolated cases. © 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.

INTRODUCTION

Congenital heart defects (CHD) occur in 5–8 per 1000 live births[1]. Neurodevelopmental impairment (NDI) occurs in a significant number of these children and was originally attributed to cardiothoracic surgery in infancy[2–5]. Abnormalities on neurological imaging prior to surgery, however, suggested that preoperative factors may influence brain development in neonates with CHD[6–8]. This raised the question as to whether circulatory changes *in utero*, caused by the CHD, could be responsible for the neurological abnormalities seen on preoperative imaging.

To study brain development *in utero*, several cohort studies have reported on head circumference (HC) as a proxy for neurocognitive outcome[9–21], as fetal head size is related directly to brain volume. These studies reported a lower mean HC in fetuses and neonates with CHD, particularly in those with hypoplastic left heart syndrome and transposition of the great arteries, compared to the average in the general population[10,13,18,20]. However, our recent, large cohort study, which made several antenatal HC measurements in cases with isolated CHD, could not replicate these results, finding only small differences in fetal head growth, with HC values that remained within the normal range, irrespective of alterations in aortic flow or saturation[12]. Two more recent, large cohort studies also opposed the hypothesis of decreased oxygenation as an explanation for smaller HC, and showed very small differences in HC between normal and CHD fetuses[15,17]. A noteable finding was that small changes in HC size were also encountered in cases with a type of CHD that does not result in fetal circulatory changes[15].

As the latter studies were unable to confirm the hypothesis of diminished fetal head growth in CHD as a result of altered fetal hemodynamics, we hypothesized that genetic effects that remained undetected in pregnancy or placental factors could play a role. To test this hypothesis, as suggested in a referee commentary[22] on our previous study[12], we retrieved from our regional registry, PRECOR, data on all fetuses with CHD, with the aim of comparing head growth patterns in fetuses with isolated *vs* those with non-isolated CHD, in order to explore if additional morbidity could explain the reduced head size found in neonates with CHD.

METHODS

This cohort study used data from three tertiary care centers in Amsterdam and Leiden: Amsterdam University Medical Centers, Amsterdam (two separate locations) and Leiden University Medical Center, Leiden. These centers collaborate in the care of children with CHD within 'CAHAL', the Center for Congenital Heart Disease Amsterdam-Leiden. CAHAL's fetal and neonatal registry is PRECOR; data collection for this registry has been described previously[23]. From PRECOR, we extracted all CHD cases diagnosed prenatally from January 2002 to July 2014, which corresponds with the timeframe of the isolated cases assessed in our previous study[12]. Not eligible for inclusion were subjects with functional CHD or primary arrhythmia with normal cardiac anatomy, and those in multiple pregnancy or with coexisting factors that are a clear cause of altered fetal head growth, such as trisomy 13 or 18, or that show an increase in fetal growth in general, such as maternal diabetes. Subjects with a severe structural brain anomaly that influences fetal head size in itself, such as hydrocephaly or holoprosencephaly, were not included. We also excluded cases in which fetal HC measurements were not available.

Fetal databases and pediatric files in the three centers were used for retrieval of data for all CHD cases, both isolated and non-isolated. We collected data regarding fetal biometry, pre- and postnatal cardiac findings, extra-cardiac abnormalities, results of genetic tests (duplications/deletions/specific gene panels), maternal information (medical and obstetric history, body mass index (BMI)) and pregnancy outcome. Gestational age was determined by first-trimester dating scan. Biometric measurements (HC and abdominal circumference (AC)) had been entered into the fetal databases prospectively, as they were part of standard fetal monitoring and therefore measured routinely. All measurements were performed according to the guidelines of the Dutch Society for Obstetrics and Gynecology[24], which are in concordance with those described by the International Society of Ultrasound in Obstetrics and Gynecology.

Data regarding postnatal cardiac diagnosis and follow-up of these CHD cases were gathered from the pediatric files. Confirmation of the CHD was based on postnatal echocardiography or postmortem examination. In cases of pregnancy termination without permission for autopsy, the cardiac diagnosis was based on prenatal echocardiography. High compliance between pre- and postnatal diagnosis in these centers, as a result of close collaboration between fetal specialists and pediatric cardiologists, has been demonstrated[25]. We retrieved complete follow-up for all liveborn cases until at least the age of 1 year. Genetic alterations or results of the assessment of a clinical geneticist, as well as extracardiac anomalies diagnosed postnatally, are included in the registry.

Cases were separated into isolated and non-isolated CHD groups according to the existence of additional morbidity. Isolated CHD was defined as the absence of genetic anomaly, extracardiac malformation and intrauterine growth restriction (IUGR)[12]. If genetic

testing was not performed, but cases did not present with additional structural malformations or signs of placental insufficiency, they were allocated to the isolated group. Minor additional findings, such as soft markers, amniotic-fluid pathology, mild pericardial effusion and/or single umbilical artery were not considered to be a significant structural malformation[12]. As the original isolated cohort described by Jansen *et al.*[12] did not include subjects from the Amsterdam University Medical Centers in the last 2.5 years, and these cases became available by data extraction from PRECOR, we supplemented the original isolated cohort of 436 cases with these subjects. Both isolated and non-isolated subjects were clustered according to the expected effect of their CHD on both aortic flow and oxygenation to the brain, based on theoretical hemodynamics, as described in our previous study[12]. A list of diagnoses assigned to each category is given in Appendix S1.

The non-isolated group was also further subdivided into three groups: cases with specific genetic alterations or evident dysmorphic features ('genetic-diagnosis group'); cases with significant extracardiac malformations but without a genetic diagnosis after consultation with a clinical geneticist ('extracardiac-malformation group'); and cases with maternal complications associated with placental pathology, including IUGR, pre-eclampsia, hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome and hemolytic uremic syndrome (HUS) ('placental-pathology group'). Cases with combined pathology, which could be allocated to more than one group, were excluded from the subgroup analysis. For example, a case with 22q11 syndrome and mild pre-eclampsia was considered non-isolated, but was not allocated to any of the three subgroups. IUGR was defined as postnatal birth weight < 3rd percentile, based on national postnatal birth-weight charts in term subjects[26]. Preterm infants were considered IUGR if either the fetal AC or the estimated fetal weight (EFW) was < 3rd centile or the AC or EFW was < 10th centile in combination with abnormal Doppler measurements in the umbilical artery at the last ultrasound scan prior to birth. These cut-offs were chosen as the postnatal birth-weight charts in our country do not exclude children who underwent planned preterm delivery due to IUGR or pre-eclampsia, resulting in charts with overrepresentation of pathology. Pre-eclampsia was defined as gestational blood pressure elevation (> 140 mmHg systolic or > 90 mmHg diastolic) combined with proteinuria (> 0.3 g/24 h, 30 mg/dL or + 1 on dipstick). The Tennesee classification was used to define HELLP syndrome[27]. To analyze centiles for both AC and EFW with advancing gestation, we used the growth curves of Verburg *et al.*[24] and Hadlock *et al.*[28].

Data analysis

The distribution of several factors that have the ability to affect fetal growth, such as maternal obesity and smoking, were compared at baseline in the isolated and non-isolated CHD groups. These two groups were also evaluated for differences in the distribution of types of CHD, with regards to their expected effect on aortic flow and saturation. We compared mean HC Z-scores at 20 weeks' gestation and fetal head growth with advancing gestation (slope of the regression) between isolated and non-isolated CHD subjects. When there were significant differences between the two groups present at baseline, mean HC and AC Z-scores were corrected for these factors. These outcome parameters were also evaluated for all non-isolated subgroups separately, compared to reference curves of the standard population[24]. The independent effect of type of comorbidity and other variables of interest on HC Z-scores was assessed amongst non-isolated CHD subjects by performing a multivariate regression analysis. We examined these data at around 20 weeks' gestation, as biometric data were available in most cases around this time.

To evaluate the effect of alterations in the intrauterine environment on head growth in CHD cases, we also estimated the expected mean HC Z-score at 36 weeks, as any effect is likely to be most evident in the last few weeks prior to birth. This was corrected for maternal age and based on the mean HC Z-score at 20 weeks and fetal head growth with advancing gestation. AC was also evaluated to relate fetal head size to intrauterine body growth.

Differences in characteristics at baseline were tested with an independent *t*-test for numerical data, while a χ^2-test was performed for all categorical variables. Biometric data (HC and AC) were converted into Z-scores to adjust for the effect of gestational age on fetal growth and to be able to relate the values observed in the dataset to those of the normal population. The growth charts by Verburg *et al.* were used to calculate Z-scores, as they included a large Dutch cohort selected over a similar period of time and these charts have been validated for the Dutch population[24,29]. In order to evaluate HC Z-scores amongst isolated and non-isolated subjects according to advancing gestation and to account for the dependency between repeated measurements, we used a mixed linear regression model with a random intercept and, if data allowed, random slope. This was necessary, as fetal biometry was measured multiple times within the same cases and the interval between the measurements could differ between cases. If data on a variable of interest were missing for > 10% of the cases, the variable was not included in the multivariate analysis. $P < 0.05$ was considered to be statistically significant. IBM SPSS statistics version 23.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.

RESULTS

Case selection

In total, we extracted from the PRECOR registry 1387 fetuses diagnosed with CHD over the study period. We excluded 64 cases with functional cardiac disease or normal cardiac anatomy on the postnatal scan, 113 cases of multiple pregnancy, 26 with maternal diabetes, 26 with structural congenital brain anomalies and 182 with trisomy 13 or 18 or triploidy. A further 60 were excluded

Figure 1 Flowchart summarizing cases included in, and excluded from, study cohort of fetuses with congenital heart defect (CHD).

because the HC measurements had not been recorded, of which 44 underwent termination of pregnancy (TOP) before 17 weeks, seven underwent TOP immediately after fetal echocardiography without routine obstetric measurements in the second trimester, eight were referrals near term in which HC measurements were technically impossible due to the head being deeply engaged and one case with ventricular septal defect was referred back to a local hospital after a single fetal echo without obstetric measurements. Thus, after exclusion of 471 cases, there were 916 cases eligible for analysis (Figure 1).

Characteristics of study subjects

Of the 916 cases analyzed, 538 had no additional pathology and were classified in the isolated CHD group; of these, 436 have been described previously[12]. In 59.9% of all isolated CHD cases, pre- or postnatal karyotyping was performed, confirming the absence of chromosomal abnormalities. In most cases, clinical genetic assessment or type of heart defect was the reason for karyotyping. Of the 378 cases with non-isolated CHD, five had combined pathology that meant they could be classified into both the genetic-diagnosis and the placental-pathology subgroups, and so were excluded from further subgroup analysis. These comprised three cases with (mild) pre-eclampsia and 22q11 syndrome, one with (mild) pre-eclampsia and mosaic trisomy 12 and one with severe HELLP syndrome and trisomy 21. The remaining 373 cases with non-isolated CHD included 213 with a chromosomal or genetic disorder, such as trisomy 21 or 22q11 syndrome, 124 with extracardiac malformation and 36 with placental pathology. There were 177 subjects with a genetic diagnosis and coexisting

Table 1 Baseline characteristics of pregnancies with fetal congenital heart defect (CHD), according to whether this was isolated

Characteristic	Isolated CHD (n = 538)	Non-isolated CHD (n = 378)	P
Fetal HC measurements			
Total (*n*)	1556	1044	
Mean *n* per case	2.9	2.8	
Maternal age (years)	30.4 ± 5.04	31.3 ± 5.70	0.02
Parity			
Nulliparous	235/535 (43.9)	145/378 (38.4)	0.09
Parous	300/535 (56.1)	233/378 (61.6)	
Maternal BMI			
≤ 25 kg/m^2	210/314 (66.9)	115/202 (56.9)	0.02
> 25 kg/m^2	104/314 (33.1)	87/202 (43.1)	
Smoking			
Non-smoker	420/464 (90.5)	303/342 (88.6)	0.38
Smoker	44/464 (9.5)	39/342 (11.4)	
Pregnancy outcome			
Live birth	373/538 (69.3)	169/378 (44.7)	
TOP	153/538 (28.4)	164/378 (43.4)	
IUFD	12/538 (2.2)	45/378 (11.9)	

Data are given as *n/N* (%) or mean $\pm$ SD unless stated otherwise. $P < 0.05$ considered statistically significant. BMI, body mass index; HC, head circumference; IUFD, intrauterine fetal demise; TOP, termination of pregnancy.

extracardiac malformation, all of which were included in the genetic-diagnosis group, because the extracardiac malformations were always part of the genetic diagnosis.

Maternal age and BMI differed significantly between the isolated CHD and non-isolated CHD groups; mothers of subjects in the non-isolated CHD group were older (difference between means = 0.9 years) and more of them had BMI > 25 kg/m^2 (difference = 10%) (Table 1).

We corrected for maternal age in all subsequent analyses. As BMI was not available in 44% of the subjects, we decided not to correct for BMI. A list of the CHD diagnoses in each of the two groups is given in Appendix S2. The CHDs in the isolated compared with the non-isolated CHD group comprised more defects that, theoretically, result in low saturation levels (8.4% *vs* 1.3%; $P < 0.001$) (Table 2). The proportion of CHDs that lead to reversed (17.5% *vs* 11.9%; $P = 0.02$) or obstructed (17.7% *vs* 10.6%; $P = 0.003$) aortic flow was also higher in the isolated compared with the non-isolated CHD cases. CHDs that cause intracardiac mixing, but do not lead to obstructed aortic flow, such as tetralogy of Fallot and pulmonary atresia with ventricular septal defect, were encountered more often amongst the non-isolated CHD cases (57.9% *vs* 33.5%; $P < 0.001$) (Table 2), as

these defects are known to be associated with genetic defects.

The mean HC Z-score was significantly lower in the non-isolated CHD cohort (Z-score $= -0.70$ (95% CI, -0.84 to -0.55)) compared with the isolated CHD cohort (Z-score $= -0.03$ (95% CI, -0.15 to 0.10)) at 20 weeks ($P < 0.001$) (Table 3). The reduction in head growth with advancing gestation was significantly greater in the non-isolated CHD cases (change in HC Z-score of -0.03 *vs* -0.01 per week; $P = 0.01$). The estimated expected mean HC Z-score at 36 weeks was -1.22 (95% CI, -1.45 to -0.98) for non-isolated CHD cases and -0.19 (95% CI, -0.36 to -0.01) for isolated CHD cases, which means both estimates still lay within the limits of normality. AC Z-scores were also significantly lower in non-isolated CHD fetuses, with a mean AC

Table 2 Distribution of congenital heart defects (CHD) in study population, with regards to their expected effect on aortic flow and oxygenation to brain, for isolated and non-isolated cases

Parameter	Isolated CHD (n (%))	Non-isolated CHD (n (%))	Total (n (%))	Difference* (95% CI) (%)	P
Oxygenation					
Low	45 (8.4)	5 (1.3)	50 (5.5)	7.1 (4.35 to 9.79)	< 0.001
Mixed	314 (58.4)	281 (74.3)	595 (65.0)	−16.0 (−21.88 to −9.79)	< 0.001
Normal	179 (33.3)	92 (24.3)	271 (29.6)	8.9 (2.96 to 14.69)	0.004
Aortic flow					
Reversed	94 (17.5)	45 (11.9)	139 (15.2)	5.6 (0.86 to 10.06)	0.02
Obstructed	95 (17.7)	40 (10.6)	135 (14.7)	7.1 (2.47 to 11.46)	0.003
Normal	349 (64.9)	293 (77.5)	642 (70.1)	−12.6 (−18.33 to −6.70)	< 0.001
Aortic flow reversed					
Oxygenation mixed	94 (17.5)	45 (11.9)	139 (15.2)	5.6 (0.86 to 10.06)	0.02
Aortic flow obstructed					
Oxygenation mixed	40 (7.4)	17 (4.5)	57 (6.2)	2.9 (−0.26 to 5.97)	0.07
Oxygenation normal	55 (10.2)	23 (6.1)	78 (8.5)	4.1 (0.46 to 7.62)	0.03
Aortic flow normal					
Oxygenation low	45 (8.4)	5 (1.3)	50 (5.5)	7.1 (4.35 to 9.79)	< 0.001
Oxygenation mixed	180 (33.5)	219 (57.9)	399 (43.6)	−24.5 (−30.69 to −17.99)	< 0.001
Oxygenation normal	124 (23.1)	69 (18.3)	193 (21.1)	4.8 (−0.59 to 9.97)	0.10

$P < 0.05$ considered statistically significant. *Isolated minus non-isolated result.

Table 3 Head circumference (HC) and abdominal circumference (AC) Z-scores in isolated and non-isolated cases of fetal congenital heart defect (CHD)

	GA 20 weeks*				GA 36 weeks†
Variable	Mean Z-score (95% CI)	P	Slope (SD/week)	P	Mean Z-score (95% CI)
HC Z-score					
Isolated CHD	−0.03 (−0.15 to 0.10)	< 0.001‡	−0.010	0.01‡	−0.19 (−0.36 to −0.01)
Non-isolated CHD	−0.70 (−0.84 to −0.55)		−0.032		−1.22 (−1.45 to −0.98)
Genetic diagnosis	−0.73 (−0.95 to −0.50)	< 0.001§	−0.037		−1.32 (−1.79 to −0.86)
Extracardiac malformation	−0.49 (−0.80 to −0.17)	0.002§	−0.023		−0.85 (−1.38 to −0.32)
Placental pathology	−1.29 (−1.97 to −0.61)	< 0.001§	−0.057		−2.20 (−3.30 to −1.10)
AC Z-score					
Isolated CHD	−0.02 (−0.15 to 0.10)	< 0.001‡	0.012	0.001‡	0.16 (−0.03 to 0.34)
Non-isolated CHD	−0.47 (−0.61 to −0.32)		−0.020		−0.79 (−1.04 to −0.54)
Genetic diagnosis	−0.47 (−0.69 to −0.26)	< 0.001§	−0.016		−1.30 (−1.76 to −0.84)
Extracardiac malformation	−0.25 (−0.62 to 0.11)	0.17§	0.002		−0.22 (−1.11 to 0.68)
Placental pathology	−1.24 (−1.84 to −0.63)	< 0.001§	−0.071		−2.37 (−3.03 to −1.72)

All values depicted were corrected for maternal age. $P < 0.05$ considered statistically significant. *Mean Z-scores and slopes calculated from biometric data. †Mean Z-scores and slopes estimated using mixed linear regression model with gestational age (GA) centered at 20 weeks. ‡Isolated *vs* non-isolated groups. §Mean HC Z-score for subgroups compared separately with normal growth reference[24] (mean Z = 0).

Z-score of −0.47 compared with −0.02 in isolated CHD cases ($P < 0.001$), and a change in AC Z-score of −0.02 per week in non-isolated *vs* change of +0.01 per week in isolated cases at 20 weeks ($P = 0.001$) (Figure 2).

Subgroup analysis

Of the 213 non-isolated CHD subjects in the genetic-diagnosis group, 143 were diagnosed with a chromosomal anomaly, including trisomy 21 ($n = 102$),

Figure 2 Head (a,c,e) and abdominal (b,d,f) growth trajectories of fetuses with congenital heart defect (CHD): (a,b) in all cases, according to whether CHD was isolated (cyan) or non-isolated (magenta); (c−f) in non-isolated CHD cases, subdivided according to additional pathology (red, genetic anomaly; green, extracardiac malformation; blue, placental pathology). Solid lines are mean and dotted lines are 95% CI. AC, abdominal circumference; HC, head circumference.

Table 4 Multivariate analysis to estimate influence of comorbidity and possible confounders on fetal head circumference (HC) at 20 gestational weeks in 373 fetuses (1031 HC measurements) with non-isolated congenital heart defect

Variable	Fetuses (n)	HC measurements (n)	Mean HC Z-score (SD)	P	Slope (SD/week) (95% CI)	P
Type of comorbidity				0.05		0.59
Extracardiac malformation	124	337	Reference		Reference	
Genetic diagnosis	213	531	−0.33 (0.10)	0.13	−0.02 (−0.07 to 0.03)	0.43
Placental pathology	36	163	−0.77 (0.02)	0.02	−0.05 (−0.12 to 0.01)	0.11
Variable of interest						
Maternal age (in years)	373	1031	0.02 (0.32)	0.27	0.001 (−0.003 to 0.004)	0.73
Smoking (yes)	39	99	−0.64 (0.02)	0.03	0.01 (−0.05 to 0.08)	0.69
Parous (yes)	233	647	−0.56 (0.01)	0.04	−0.02 (−0.06 to 0.03)	0.44

Mean HC Z-scores and slopes estimated using mixed linear regression model with gestational age centered at 20 weeks. $P < 0.05$ considered statistically significant.

Turner syndrome ($n = 20$), mosaic variegated aneuploidy syndrome ($n = 3$), unbalanced translocation ($n = 14$) and other chromosomal anomaly ($n = 4$). The other 70 subjects had a genetic diagnosis, including 22q11.2 microdeletion syndrome ($n = 27$), CHARGE syndrome ($n = 4$), VACTERL association ($n = 4$), Noonan syndrome ($n = 3$), another miscellaneous genetic syndrome ($n = 15$), duplication ($n = 8$), deletion > 5 Mb on array comparative genomic hybridization ($n = 7$), or a strong clinical suspicion for a specific genetic syndrome without further diagnostic tests ($n = 2$). Significant extracardiac abnormalities were encountered in 124 subjects without a genetic diagnosis or dysmorphic features (extracardiac-malformation group). The 36 subjects presenting with placental pathology resulting in impaired fetal growth (placental-pathology group) included subjects with pre-eclampsia ($n = 8$), HELLP ($n = 2$), HUS ($n = 1$) and IUGR without maternal disease ($n = 25$).

We evaluated the HC Z-scores, corrected for maternal age, for these three subgroups separately (Table 3). All three subgroups showed a reduction in HC compared to the normal growth charts[24]. Subjects with a genetic anomaly had a mean HC Z-score at 20 weeks of −0.73 ($P < 0.001$) and an estimated Z-score at 36 weeks of −1.32. The extracardiac-malformation group had a mean HC Z-score at 20 weeks of −0.49 ($P = 0.002$) and an estimated Z-score at 36 weeks of −0.85. The placental-pathology group showed the greatest negative effect on fetal HC; the mean HC Z-score at 20 weeks in this group was −1.29 ($P < 0.001$), which decreased further to an estimated HC Z-score of −2.20 at 36 weeks. The mean AC Z-scores for each subgroup are presented in Table 3.

Multivariate analysis

The multivariate analysis to evaluate the influence of type of comorbidity, maternal age, smoking and being parous on mean HC Z-score and intrauterine fetal head growth at 20 weeks in all non-isolated CHD subjects is summarized in Table 4. Corrected for the other variables of interest, the presence of placental pathology, smoking and being parous appeared to be significant independent risk factors for a lower HC Z-score at 20 weeks' gestation. Additional pathology and being parous also tended to have a negative effect on head growth progression (slope) at 20 weeks.

DISCUSSION

Fetuses with non-isolated CHD had a significantly smaller HC at midgestation and more constrained head growth towards the end of pregnancy, compared with fetuses with isolated CHD. Although the mean HC Z-score prior to delivery was −1.2 amongst CHD cases with additional pathology, compared with −0.2 in isolated CHD cases, both estimates still lie within the limits of normality. The decrease in HC appeared most prominent amongst subjects with placenta-related pathology.

Most studies that have explored fetal HC in CHD compared their findings to head size in normal fetuses[9,14,15,21,30–32] and did not strictly exclude non-isolated cases[11,16,21,30,33,34]. As our cases originate from a large regional cohort with follow-up, we were able to analyze differences between non-isolated and isolated cases, and to test specific subgroups separately, with clustering of specific CHD types. All non-isolated CHD subgroups showed a significant decrease in head growth compared with normal charts. The largest effect was encountered in fetuses affected by placental pathology, followed by those with a genetic diagnosis and those with an extracardiac malformation. The progressive decline in (head) growth towards the end of pregnancy, encountered in all three subgroups, is a feature of placental insufficiency and characterized by a decrease in the ability to reach a certain growth potential with advancing gestation[35]. This implies that cases with a genetic diagnosis or extracardiac malformation as well as truly isolated cases did not reach their genetic growth potential, despite measurements lying within the limits of normality[36].

The types of CHD differed significantly between the isolated CHD and the non-isolated CHD groups. The isolated CHD group, in which HC growth was decreased only minimally, included significantly more CHDs that result in low cerebral oxygenation, such as transposition of the great arteries. CHDs that cause decreased flow towards the brain (e.g. aortic coarctation and hypoplastic left heart syndrome) were also encountered more frequently amongst cases of isolated CHD. Non-isolated CHD subjects, in which impaired head growth was most pronounced, had mainly CHDs without any hemodynamic effect on aortic flow

(e.g. tetralogy of Fallot). If our previously raised hypothesis[12], that diminished fetal head growth in CHD is a result of altered fetal hemodynamics, is correct, it should have been head growth in the isolated group that was the more severely decreased, but our current findings indicate the opposite. Reduced head size cannot, therefore, be attributed to altered cerebral hemodynamics.

Recent studies support that both growth restriction (17–18%) and placenta-related complications, such as pre-eclampsia, occur more frequently in CHD cases[15,36–41]. However, as previous studies reporting on HC in CHD did not look at birth weight, growth trajectories or additional genetic pathology, their findings may, in our opinion, be explained by additional pathology.

As all three non-isolated CHD subgroups in our study showed some form of growth restriction, it is possible that a common factor, involving both the development of CHD and the placenta, could play a role. The levels of (anti-)angiogenetic markers, including placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), vascular endothelial growth factor (VEGF) and other factors associated with chronic hypoxia, are altered (increased or decreased) in CHD subjects[42,43]. These factors have been proven to be related to embryonic and cardiac development as well[44–49], and overexpression has been shown to result in abnormal heart development[47,50]. Lower oxygen saturation levels in the umbilical vein[42,43] and increased resistance in the umbilical artery[19], which are additional signs of impaired placental function, have also been reported in CHD pregnancies. This angiogenic imbalance is also encountered in placental tissue derived from IUGR fetuses[51]. Altered levels of PlGF and sFlt-1 have been shown to be associated with a higher risk for IUGR and developing pre-eclampsia[52–54]. This similarity of antiangiogenic environment in subjects with CHD and those with IUGR implies that the pathophysiology of both diseases might share a common pathway[36,47].

Furthermore, it seems that (head) growth restriction is linked to specific CHDs[12,15,36,55,56]. Differences in the VEGF signalling pathway have been shown to affect endocardial cushion formation and septation of the cardiac chambers, and may result in aberrant aortic arch artery patterning and outflow tract anomalies[47,57,58]. Future research should assess large cohorts and, if available, biobanks, to explore this further. The findings in our cohort highlight that future studies on fetal (brain) development should not be undertaken without analysis of fetal growth and additional morbidity.

As head growth is multifactorial and the direct relationship with neurodevelopmental outcome has not yet been studied in strictly isolated cases[11,21], it is debatable whether HC should be used as a proxy. It was found that decreased somatic growth, rather than head growth, might be an important predictor for NDI in a group with specific types of CHD[11,21]. Results of a recent Dutch cohort support this, as a smaller AC and lower EFW were risk factors for NDI, whereas HC alone was not[59].

A limitation of our study is the fact that the biometric data were not distributed equally throughout pregnancy in non-isolated compared with isolated CHD cases, due to the higher incidence of TOP and intrauterine fetal demise in the non-isolated CHD group. Furthermore, genetic testing was not performed in several cases for the same reason. Although completeness of data is rarely possible in retrospective cohorts, information was available in a significant proportion of cases, as follow-up was complete until at least 1 year of age. The current literature lacks information on the impact of additional pathology, as this has not, to our knowledge, been studied before in such a large cohort.

Our results show that the presence of additional pathology has a large effect on head growth in fetuses with CHD, which is more pronounced than the effect of aortic flow or saturation in these cases. The factor contributing most seems to be abnormal placentation, although genetic anomaly also plays an important role. Pathways involved in both the development of CHD and fetal growth appear to influence head growth more than does the CHD itself. Future research on brain development in CHD fetuses and infants should, therefore, relate to overall growth and additional pathology.

REFERENCES

1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. *J Am Coll Cardiol* 2002; 39: 1890–1900.
2. Jones B, Muscara F, Lloyd O, McKinlay L, Justo R. Neurodevelopmental outcome following open heart surgery in infancy: 6-year follow-up. *Cardiol Young* 2015; 25: 903–910.
3. Sarrechia I, Miatton M, De Wolf D, Francois K, Gewillig M, Meyns B, Vingerhoets G. Neurocognitive development and behaviour in school-aged children after surgery for univentricular or biventricular congenital heart disease. *Eur J Cardiothorac Surg* 2016; 49: 167–174.
4. Snookes SH, Gunn JK, Eldridge BJ, Donath SM, Hunt RW, Galea MP, Shekerdemian L. A systematic review of motor and cognitive outcomes after early surgery for congenital heart disease. *Pediatrics* 2010; 125: e818–827.
5. Mulkey SB, Bai S, Luo C, Cleavenger JE, Gibson N, Holland G, Mosley BS, Kaiser JR, Bhutta AT. School-Age Test Proficiency and Special Education After Congenital Heart Disease Surgery in Infancy. *J Pediatr* 2016; 178: 47–54.e1.
6. Khalil A, Suff N, Thilaganathan B, Hurrell A, Cooper D, Carvalho JS. Brain abnormalities and neurodevelopmental delay in congenital heart disease: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2014; 43: 14–24.
7. Limperopoulos C, Majnemer A, Shevell MI, Rohlicek C, Rosenblatt B, Tchervenkov C, Darwish HZ. Predictors of developmental disabilities after open heart surgery in young children with congenital heart defects. *J Pediatr* 2002; 141: 51–58.
8. Owen M, Shevell M, Majnemer A, Limperopoulos C. Abnormal brain structure and function in newborns with complex congenital heart defects before open heart surgery: a review of the evidence. *J Child Neurol* 2011; 26: 743–755.
9. Arduini M, Rosati P, Caforio L, Guariglia L, Clerici G, Di Renzo GC, Scambia G. Cerebral blood flow autoregulation and congenital heart disease: possible causes of abnormal prenatal neurologic development. *J Matern Fetal Neonatal Med* 2011; 24: 1208–1211.
10. Barbu D, Mert I, Kruger M, Bahado-Singh RO. Evidence of fetal central nervous system injury in isolated congenital heart defects: microcephaly at birth. *Am J Obstet Gynecol* 2009; 201: 43.e1–7.
11. Hahn E, Szwast A, Cnota J, 2nd, Levine JC, Fifer CG, Jaeggi E, Andrews H, Williams IA. Association between fetal growth, cerebral blood flow and neurodevelopmental outcome in univentricular fetuses. *Ultrasound Obstet Gynecol* 2016; 47: 460–465.
12. Jansen FA, van Zwet EW, Rijlaarsdam ME, Pajkrt E, van Velzen CL, Zuurveen HR, Kragt A, Bax CL, Clur SA, van Lith JM, Blom NA, Haak MC. Head growth in fetuses with isolated congenital heart defects: lack of influence of aortic arch flow and ascending aorta oxygen saturation. *Ultrasound Obstet Gynecol* 2016; 48: 357–364.
13. Manzar S, Nair AK, Pai MG, Al-Khusaiby SM. Head size at birth in neonates with transposition of great arteries and hypoplastic left heart syndrome. *Saudi Med J* 2005; 26: 453–456.
14. Masoller N, Martinez JM, Gomez O, Bennasar M, Crispi F, Sanz-Cortes M, Egana-Ugrinovic G, Bartrons J, Puerto B, Gratacos E. Evidence of second-trimester changes in head biometry and brain perfusion in fetuses with congenital heart disease. *Ultrasound Obstet Gynecol* 2014; 44: 182–187.
15. Matthiesen NB, Henriksen TB, Gaynor JW, Agergaard P, Bach CC, Hjortdal VE, Ostergaard JR. Congenital Heart Defects and Indices of Fetal Cerebral Growth in a Nationwide Cohort of 924 422 Liveborn Infants. *Circulation* 2016; 133: 566–575.
16. McElhinney DB, Benson CB, Brown DW, Wilkins-Haug LE, Marshall AC, Zaccagnini L, Tworetzky W. Cerebral blood flow characteristics and biometry in fetuses undergoing prenatal intervention for aortic stenosis with evolving hypoplastic left heart syndrome. *Ultrasound Med Biol* 2010; 36: 29–37.

17. Mebius MJ, Clur SAB, Vink AS, Pajkrt E, Kalteren WS, Kooi EMW, Bos AF, du Marchie Sarvaas GJ, Bilardo CM. Growth patterns and cerebroplacental hemodynamics in fetuses with congenital heart disease. *Ultrasound Obstet Gynecol* 2019; **53**: 769–778.

18. Rosenthal GL. Patterns of prenatal growth among infants with cardiovascular malformations: possible fetal hemodynamic effects. *Am J Epidemiol* 1996; **143**: 505–513.

19. Ruiz A, Cruz-Lemini M, Masoller N, Sanz-Cortes M, Ferrer Q, Ribera I, Martinez JM, Crispi F, Arevalo S, Gomez O, Perez-Hoyos S, Carreras E, Gratacos E, Llurba E. Longitudinal changes in fetal biometry and cerebroplacental hemodynamics in fetuses with congenital heart disease. *Ultrasound Obstet Gynecol* 2017; **49**: 379–386.

20. Shillingford AJ, Ittenbach RF, Marino BS, Rychik J, Clancy RR, Spray TL, Gaynor JW, Wernovsky G. Aortic morphometry and microcephaly in hypoplastic left heart syndrome. *Cardiol Young* 2007; **17**: 189–195.

21. Williams IA, Fifer WP, Andrews H. Fetal Growth and Neurodevelopmental Outcome in Congenital Heart Disease. *Pediatr Cardiol* 2015; **36**: 1135–1144.

22. Carvalho JS. Re: Head growth in fetuses with isolated congenital heart defects: lack of influence of aortic arch flow and ascending aorta oxygen saturation. F. A. R. Jansen, E. W. van Zwet, M. E. B. Rijlaarsdam, E. Pajkrt, C. L. van Velzen, H. R. Zuurveen, A. Kragt, C. L. Bax, S.-A. B. Clur, J. M. M. van Lith, N. A. Blom and M. C. Haak. *Ultrasound Obstet Gynecol* 2016; **48**: 357–364 [Refereree Commentary]. *Ultrasound Obstet Gynecol* 2016; **48**: 282.

23. van Velzen CL, Clur SA, Rijlaarsdam ME, Bax CJ, Pajkrt E, Heymans MW, Bekker MN, Hruda J, de Groot CJ, Blom NA, Haak MC. Prenatal diagnosis of congenital heart disease--results of a national screening programme. *BJOG* 2016; **123**: 400–407.

24. Verburg BO, Steegers EA, De Ridder M, Snijders RJ, Smith E, Hofman A, Moll HA, Jaddoe VW, Witteman JC. New charts for ultrasound dating of pregnancy and assessment of fetal growth: longitudinal data from a population-based cohort study. *Ultrasound Obstet Gynecol* 2008; **31**: 388–396.

25. van Velzen CL, Clur SA, Rijlaarsdam ME, Pajkrt E, Bax CJ, Hruda J, de Groot CJ, Blom NA, Haak MC. Prenatal diagnosis of congenital heart defects: accuracy and discrepancies in a multicenter cohort. *Ultrasound Obstet Gynecol* 2016; **47**: 616–622.

26. Hoftiezer L, Hof MHP, Dijs-Elsinga J, Hogeveen M, Hukkelhoven CWPM, van Lingen RA. From population reference to national standard: new and improved birthweight charts. *Am J Obstet Gynecol* 2019; **220**: 383.e1–17.

27. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. *Obstet Gynecol* 2004; **103**: 981–991.

28. Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. *Radiology* 1991; **181**: 129–133.

29. van de Kamp K, Pajkrt E, Zwinderman AH, van der Post JA, Snijders RJM. Validation of Reference Charts for Mid-Trimester Fetal Biometry. *Fetal Diagn Ther* 2019; **45**: 42–49.

30. Donofrio MT, Bremer YA, Schieken RM, Gennings C, Morton LD, Eidem BW, Cetta F, Falkensammer CB, Huhta JC, Kleinman CS. Autoregulation of cerebral blood flow in fetuses with congenital heart disease: the brain sparing effect. *Pediatr Cardiol* 2003; **24**: 436–443.

31. Itsukaichi M, Kikuchi A, Yoshihara K, Serikawa T, Takakuwa K, Tanaka K. Changes in fetal circulation associated with congenital heart disease and their effects on fetal growth. *Fetal Diagn Ther* 2011; **30**: 219–224.

32. Zeng S, Zhou QC, Zhou JW, Li M, Long C, Peng QH. Volume of intracranial structures on three-dimensional ultrasound in fetuses with congenital heart disease. *Ultrasound Obstet Gynecol* 2015; **46**: 174–181.

33. Hangge PT, Cnota JF, Woo JG, Hinton AC, Divanovic AA, Manning PB, Ittenbach RF, Hinton RB. Microcephaly is associated with early adverse neurologic outcomes in hypoplastic left heart syndrome. *Pediatr Res* 2013; **74**: 61–67.

34. Hinton RB, Andelfinger G, Sekar P, Hinton AC, Gendron RL, Michelfelder EC, Robitaille Y, Benson DW. Prenatal head growth and white matter injury in hypoplastic left heart syndrome. *Pediatr Res* 2008; **64**: 364–369.

35. Wolf H. Foetale groeibeperking Versie 2,1: NVOG Nederlandse Vereniging voor Obstetrie & Gynaecologie 2008; 25.

36. Haveman I, Fleurke-Rozema JH, Mulder EJH, Benders M, du Marchie Sarvaas G, Ter Heide H, de Heus RH, Bilardo CM. Growth patterns in fetuses with isolated cardiac defects. *Prenat Diagn* 2018; **38**: 328–336.

37. Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. *Pediatrics* 1988; **82**: 83–90.

38. Levy RJ, Rosenthal A, Fyler DC, Nadas AS. Birthweight of infants with congenital heart disease. *Am J Dis Child* 1978; **132**: 249–254.

39. Ruiz A, Ferrer Q, Sanchez O, Ribera I, Arevalo S, Alomar O, Mendoza M, Cabero L, Carrerras E, Llurba E. Placenta-related complications in women carrying a foetus with congenital heart disease. *J Matern Fetal Neonatal Med* 2016; **29**: 3271–3275.

40. Albalawi A, Brancusi F, Askin F, Ehsanipoor R, Wang J, Burd I, Sekar P. Placental Characteristics of Fetuses With Congenital Heart Disease. *J Ultrasound Med* 2017; **36**: 965–972.

41. Rychik J, Goff D, McKay E, Mott A, Tian Z, Licht DJ, Gaynor JW. Characterization of the Placenta in the Newborn with Congenital Heart Disease: Distinctions Based on Type of Cardiac Malformation. *Pediatr Cardiol* 2018; **39**: 1165–1171.

42. Llurba E, Sanchez O, Ferrer Q, Nicolaides KH, Ruiz A, Dominguez C, Sanchez-de-Toledo J, Garcia-Garcia B, Soro G, Arevalo S, Goya M, Suy A, Perez-Hoyos S, Alijotas-Reig J, Carreras E, Cabero L. Maternal and foetal angiogenic imbalance in congenital heart defects. *Eur Heart J* 2014; **35**: 701–707.

43. Llurba E, Syngelaki A, Sanchez O, Carreras E, Cabero L, Nicolaides KH. Maternal serum placental growth factor at 11–13 weeks' gestation and fetal cardiac defects. *Ultrasound Obstet Gynecol* 2013; **42**: 169–174.

44. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. *Mol Hum Reprod* 2001; **7**: 205–210.

45. Shiraishi S, Nakagawa K, Kinukawa N, Nakano H, Sueishi K. Immunohistochemical localization of vascular endothelial growth factor in the human placenta. *Placenta* 1996; **17**: 111–121.

46. Bussmann J, Bakkers J, Schulte-Merker S. Early endocardial morphogenesis requires Scl/Tal1. *PLoS Genet* 2007; **3**: e140.

47. Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. *Development* 2000; **127**: 3941–3946.

48. Accornero F, Molkentin JD. Placental growth factor as a protective paracrine effector in the heart. *Trends Cardiovasc Med* 2011; **21**: 220–224.

49. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, VandenDriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med* 2001; **7**: 575–583.

50. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard JC, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D'Amore PA, Shima DT. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. *Nat Med* 1999; **5**: 495–502.

51. Barut F, Barut A, Gun BD, Kandemir NO, Harma MI, Harma M, Aktunc E, Ozdamar SO. Intrauterine growth restriction and placental angiogenesis. *Diagn Pathol* 2010; **5**: 24.

52. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. *Ultrasound Obstet Gynecol* 2008; **32**: 732–739.

53. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest* 2003; **111**: 649–658.

54. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive Value of the sFlt-1: PlGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med* 2016; **374**: 13–22.

55. Turan S, Rosenbloom JI, Hussein M, Berg C, Gembruch U, Baschat AA, Turan OM. Longitudinal analysis of head and somatic growth in fetuses with congenital heart defects. *J Clin Ultrasound* 2017; **45**: 96–104.

56. Puri K, Warshak CR, Habli MA, Yuan A, Sahay RD, King EC, Divanovic A, Cnota JF. Fetal somatic growth trajectory differs by type of congenital heart disease. *Pediatr Res* 2018; **83**: 669–676.

57. Stankunas K, Ma GK, Kuhnert FJ, Kuo CJ, Chang CP. VEGF signaling has distinct spatiotemporal roles during heart valve development. *Dev Biol* 2010; **347**: 325–336.

58. Stalmans I, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der Ohe M, Swillen A, Maes C, Gewillig M, Molin DG, Hellings P, Boetel T, Haardt M, Compernolle V, Dewerchin M, Plaisance S, Vlietinck R, Emanuel B, Gittenberger-de Groot AC, Scambler P, Morrow B, Driscol DA, Moons L, Esguerra CV, Carmeliet G, Behn-Krappa A, Devriendt K, Collen D, Conway SJ, Carmeliet P. VEGF: a modifier of the del22q11 (DiGeorge) syndrome? *Nat Med* 2003; **9**: 173–182.

59. van Batenburg-Eddes T, de Groot L, Steegers EA, Hofman A, Jaddoe VW, Verhulst FC, Tiemeier H. Fetal programming of infant neuromotor development: the generation R study. *Pediatr Res* 2010; **67**: 132–137.

SUPPORTING INFORMATION ON THE INTERNET

The following supporting information may be found in the online version of this article:

Appendix S1 Distribution of individual, prenatal-ultrasound diagnoses, based on their effect on oxygen delivery to brain and flow through aortic arch, in cases of isolated and of non-isolated congenital heart defect

Appendix S2 List of primary diagnoses per group (as confirmed postnatally), based on their proportion within this cohort and risk for additional pathology